ClinicalTrials.gg
CompletedNCT00496834Updated May 22, 2024Results posted

LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

A Phase 4 interventional study of losartan potassium and Comparator: carvedilol in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
22nd of 65
201 · median 100
Started
2008
with 5 others
Phase 4
26 of 65
2 open now
Registered
9th of 65
by date
Lead sponsor
7 of 65
Organon and Co

Among the 65 studies testing losartan in Hypertension, this one is the 22nd largest by enrollment, is one of 6 that started in 2008, is one of 26 in phase 4, and was the 9th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the essential hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female adults, 18 years or over
  • Essential Hypertension with mean SBP (systolic blood pressure) ≥ 140 mm Hg or mean DBP (diastolic blood pressure) ≥ 90 mm Hg* when blood pressure is measured at Visit 1(week -2) and at Visit 2(week 0).

If diabetes patients, mean SBP ≥ 130 mm Hg or mean DBP ≥ 80 mm Hg (Mean of blood pressure values measured consecutively at least 2 minutes apart)

  • Patient who is willing to, and is able to sign the form

Exclusion criteria

Exclusion Criteria:

  • Patient Is Pregnant Or Breastfeeding, Or Expecting To Conceive Within The Projected Duration Of The Study
  • Patient Has Known Or Suspected Secondary Hypertension Of Any Etiology
  • Patient has history of malignant hypertension
  • Patient has history of cerebrovascular accident (cerebral infarction) or myocardiac infarction within the last 6 months
  • Patient takes antihypertensive drugs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    1

    Losartan or Losartan/HCTZ

    Drug: losartan potassium · Drug: Comparator: losartan (+) hydrochlorothiazide (HCTZ)

  • Active comparator
    2

    Carvedilol or Carvedilol/HCTZ

    Drug: Comparator: carvedilol · Drug: Comparator: carvedilol (+) hydrochlorothiazide

Interventions

  • Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)

  • Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)

  • DrugComparator: losartan (+) hydrochlorothiazide (HCTZ)

    Drug page: Hydrochlorothiazide

    Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)

  • DrugComparator: carvedilol (+) hydrochlorothiazide

    Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)

06

What researchers measure

Primary outcomes

  1. Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug

    Analysis was performed in the modified intention to treat (mITT) population.

    Time frame: Baseline and 24 Weeks

  2. PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug

    Analysis was performed in the per protocol (PP) population which additionally excludes certain protocol violations as described in the analysis plan.

    Time frame: Baseline and 24 Weeks

Secondary outcomes

  1. Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug

    Time frame: Baseline and 24 weeks

  2. Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug

    Time frame: Baseline and 24 weeks

07

Results

Posted Dec 15, 2010

Participant flow

7 centers participated in this study (7 medical centers of university). FPE (First patient enrolled): Feb-2008, FPI (First patient in): Feb-2008, LPO (Last patient out): Sep-2009

Participant flow — Overall Study
MilestoneLosartanCarvedilol
Started101100
Completed8387
Not completed1813
Withdrew: Withdrawal by subject46
Withdrew: Contraindicated medication administered01
Withdrew: Inclusion/exclusion criteria not met32
Withdrew: Adverse event53
Withdrew: Ip administration violation20
Withdrew: Lost to follow-up20
Withdrew: Blood pressure control failure21

Outcome measures

PrimaryPulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug

Analysis was performed in the modified intention to treat (mITT) population.

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · meters/second
Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
meters/secondLosartanCarvedilol
Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug0.28 ± 1.29-0.12 ± 1.55
Statistical analysis
  • Losartan vs Carvedilol · Mean difference (final values): -0.41 · 95% CI -0.83 to 0.01The lower limit of ≥-1.5m/s was judged to prove the non-inferiority of the test group to the control group.
PrimaryPWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug

Analysis was performed in the per protocol (PP) population which additionally excludes certain protocol violations as described in the analysis plan.

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · meters/second
PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
meters/secondLosartanCarvedilol
PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug0.16 ± 1.25-0.20 ± 1.50
Statistical analysis
  • Losartan vs Carvedilol · Mean difference (final values): -0.36 · 95% CI -0.86 to 0.15The lower limit of ≥-1.5m/s was judged to prove the non-inferiority of the test group to the control group.
SecondarySystolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
Time frame:
Baseline and 24 weeks
Reported as:
Mean · mm Hg
Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
mm HgLosartanCarvedilol
Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug-15.08 ± 14.59-14.81 ± 15.38
Statistical analysis
  • Losartan vs Carvedilol · t-test, 2 sided · p = 0.9032 (Significance level=0.05)The secondary efficacy analysis was performed in the modified intention to treat population using t-test.
SecondaryDiastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
Time frame:
Baseline and 24 weeks
Reported as:
Mean · mm Hg
Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
mm HgLosartanCarvedilol
Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug-8.43 ± 9.29-7.81 ± 9.61
Statistical analysis
  • Losartan vs Carvedilol · t-test, 2 sided · p = 0.6574 (Significance level=0.05)The secondary efficacy analysis was performed in the modified intention to treat population using t-test

Adverse events

Collected over Adverse events were recorded from first administration of study drug up to 14 days after the administration of final dose.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Losartan—5/101 (5%)35/101 (34.7%)
Carvedilol—6/100 (6%)51/100 (51%)
Most frequent serious events
Most frequent serious events
EventLosartanCarvedilol
OverdoseInjury, poisoning and procedural complications1/1015/100
Myelitis transverseNervous system disorders0/1011/100
Chronic sinusitisInfections and infestations0/1011/100
Mouth haemorrhageGastrointestinal disorders1/1010/100
Ligament sprainInjury, poisoning and procedural complications1/1010/100
Prinzmetal anginaCardiac disorders1/1010/100
HaematomaVascular disorders1/1010/100
Most frequent other events
Showing 10 of 69
Most frequent other events
EventLosartanCarvedilol
HeadacheNervous system disorders8/1019/100
NasopharyngitisInfections and infestations4/1017/100
DizzinessNervous system disorders5/1013/100
DyspepsiaGastrointestinal disorders3/1013/100
NauseaGastrointestinal disorders0/1013/100
Chest painGeneral disorders2/1013/100
Erectile dysfunctionReproductive system and breast disorders0/1013/100
Dizziness posturalNervous system disorders0/1012/100
Duodenal ulcerGastrointestinal disorders0/1012/100
Chest discomfortGeneral disorders2/1012/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)LosartanCarvedilolTotal
Mean49.0 ± 9.350.1 ± 10.249.6 ± 9.7
Age, Customized
Age, Customized(participants)LosartanCarvedilolTotal
>= 18 to < 65 years9691187
>=65 years5914
Sex: Female, Male
Sex: Female, Male(Participants)LosartanCarvedilolTotal
Female6357120
Male384381
DBP (diastolic blood pressure)
DBP (diastolic blood pressure)(mm Hg)LosartanCarvedilolTotal
Mean96.4 ± 8.896.4 ± 8.396.4 ± 8.5
Height
Height(Centimeters)LosartanCarvedilolTotal
Mean164.9 ± 7.8163.3 ± 9.2164.1 ± 8.5
PWV (pulse wave velocity)
PWV (pulse wave velocity)(meters/second)LosartanCarvedilolTotal
Mean7.6 ± 1.47.7 ± 1.47.6 ± 1.4
Pulse
Pulse(BPM (beats per minute))LosartanCarvedilolTotal
Mean71.8 ± 10.072.3 ± 10.072.0 ± 10.0
SBP (systolic blood pressure)
SBP (systolic blood pressure)(mm Hg)LosartanCarvedilolTotal
Mean150.6 ± 11.0152.7 ± 12.1151.6 ± 11.6

1 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2008 to primary completion in Sep 2009, 19 months.

Results were first posted in Dec 2010, 1 year 3 months after primary completion.

Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is below that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2007
First posted
Jul 4, 2007
StartActual
Feb 1, 2008
Primary completionActual
Sep 1, 2009
CompletionActual
Sep 1, 2009
Results first posted
Dec 15, 2010
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00496834
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jul 4, 2007
Start date
Feb 1, 2008
Primary completion
Sep 1, 2009
Completion
Sep 1, 2009
Results posted
Dec 15, 2010
Last update
May 22, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion